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Huntington’s disease is a progressive neurodegenerative disorder characterized by motor, cognitive and psychiatric symptoms.
Currently, no disease-modifying therapies are available to slow or halt disease progression. Huntington’s disease is characterized
by relatively focal and specific loss of striatal medium spiny neurons, which makes it suitable for cell-replacement therapy, a pro-
cess involving the transplantation of donor cells to replace those lost due to disease. TRIal DEsigns for delivery of Novel Therapies
in neurodegeneration is a phase I Trial Within a Cohort designed to assess safety and feasibility of transplanting human foetal stri-
atal cells into the striatum of people with Huntington’s disease. A minimum of 18 participants will be enrolled in the study cohort,
and up to five eligible participants will be randomly selected to undergo transplantation of 12–22 million foetal cells in a dose es-
calation paradigm. Independent reviewers will assess safety outcomes (lack of significant infection, bleeding or new neurological
deficit) 4 weeks after surgery, and ongoing safety will be established before conducting each subsequent surgery. All participants
will undergo detailed clinical and functional assessment at baseline (6 and 12 months). Surgery will be performed 1 month after
baseline, and transplant participants will undergo regular clinical follow-up for at least 12 months. Evaluation of trial processes
will also be undertaken. Transplant participants and their carers will be interviewed 1 month before and after surgery. Interviews
will also be conducted with non-transplanted participants and healthcare staff delivering the intervention and involved in the clinic-
al care of participants. Evaluation of clinical and functional efficacy outcomes and intervention costs will be carried out to explore
plausible trial designs for subsequent randomized controlled trials aimed at evaluating efficacy and cost-effectiveness of cell-replace-
ment therapy. TRIal DEsigns for delivery of Novel Therapies in neurodegeneration will enable the assessment of the safety, feasi-
bility, acceptability and cost of foetal cell transplants in people with Huntington’s disease. The data collected will inform trial
designs for complex intra-cranial interventions in a range of neurodegenerative conditions and facilitate the development of stable
surgical pipelines for delivery of future stem cell trials.
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Introduction
Huntington’s disease is an inherited neurodegenerative
condition characterized by progressive motor, cognitive
and psychiatric deficits that significantly erode quality of
life, resulting in a substantial societal cost (Jones et al.,
2016). Huntington’s disease is largely untreatable and no
disease-modifying therapies currently exist. However, the
relatively focal loss of medium spiny neurons in the stri-
atum makes it a suitable candidate for cell-replacement
therapy (CRT), in which donor cells are transplanted to
replace those lost due to disease, with the expectation
that the transplanted cells will re-establish some degree of
normal neural circuitry.
An early target for CRT as a potential therapeutic
strategy was Parkinson’s disease, with the aim of replac-
ing degenerated mid-brain dopaminergic neurons.
Transplants of human foetal-derived dopaminergic
progenitors in Parkinson’s disease have been shown to
produce significant and sustained benefit, establishing im-
portant proof of principle for CRT in general (Petit
et al., 2014; Barker et al., 2015), albeit the key factors
important for reliable benefit are still being explored
through studies such as the ongoing Transeuro trial
(Barker et al., 2019). Early promise in Parkinson’s disease
encouraged the exploration of CRT in Huntington’s dis-
ease. Here, the demands on the transplant are theoretical-
ly greater in that the transplanted tissue needs to
reconstruct key elements of the host neural circuitry in
order to provide functional benefit (Brasted et al., 1999;
Döbrössy and Dunnett, 2001; Mazzocchi-Jones et al.,
2009). This is in contrast to Parkinson’s disease where
local release of dopamine may be sufficient to improve
function. Thus, CRT in Huntington’s disease represents a
more rigorous test of neural network reconstruction
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Transplants of foetal striatal tissue in animal models of
Huntington’s disease have demonstrated transplant sur-
vival, integration and alleviation of both functional motor
and cognitive deficits (Dunnett et al., 2000).
Subsequently, several open label trials transplanting
human foetal striatal cells into limited numbers of
Huntington’s disease participants have reported safety
and feasibility [reviewed in (Rosser and Bachoud-Lévi,
2012)]. The most success to date comes from a pilot
study of Bachoud-Lévi et al. (2000) who transplanted
foetal striatal tissue pieces into five patients with
Huntington’s disease and reported MRI and fluorodeoxy-
glucose PET evidence of graft survival, associated with
improvement in cognition and mobility, in three of the
five patients, whereas the two patients with no graft sur-
vival did not improve clinically. However, these effects
appeared to wane by 10 years (Bachoud-Lévi et al., 2000,
2006; Bachoud-Lévi, 2009) with some evidence of an on-
going low-grade immunological reaction (Krystkowiak
et al., 2007). A larger study, MIG-HD, undertaken by
Bachoud-Lévi and colleagues between 2000 and 2012
was less successful than their pilot study in terms of sur-
vival of functioning grafts (Bachoud-Lévi et al., 2020a).
The processes in MIG-HD differed from the pilot trial in
several important respects and raised issues relating to
foetal tissue preparation, potential alloimmunization to
graft material, surgical fidelity and trial design reviewed
in Bachoud-Levi et al. (2020b), which have been key to
the design of TRIal DEsigns for delivery of Novel
Therapies in neurodegeneration (TRIDENT).
An alternative approach to preparing the donor foetal
striatal promordia as tissue pieces is to prepare them as a
cell suspension. The NEST-UK study (ISRCTN
36485475) used dissociated cells, demonstrating safety
and feasibility in four participants who received staged
bi-lateral striatal cell transplants and one who received
simultaneous bilateral transplants with up to 12 million
cells per side (Rosser et al., 2002; Barker et al., 2013).
However, there was no clear, demonstrable functional im-
provement, perhaps reflecting the small participant num-
bers and the small graft deposits seen on imaging (Barker
et al., 2013), the latter suggesting that insufficient num-
ber of donor cells were transplanted (a consequence of
the overriding safety concern at the time being potential
tissue overgrowth). However, overgrowth was not
observed, and the need for studies transplanting greater
cell numbers has since become evident (in TRIDENT we
plan to use the maximum used in NEST-UK as the min-
imum dose). Although the current clinical evidence pro-
vides some proof of principle that transplantation of
foetal striatal progenitor cells may improve function in
Huntington’s disease, the available data do not yet dem-
onstrate it to be a robust and reliable therapeutic option,
and thus further investigation is warranted. A future aim
will be to replace foetal-derived cells with donor cells
derived from a pluripotent stem cell source which will be
more practically and ethically sustainable. However, at
the time of writing, stem cell-derived products are not
ready for clinical trial and hence a foetal-derived product
provides the only cell source that has been documented
for clinical application and which can be used to address
clinical translation challenges and to gather further data
on the safety and efficacy of CRT in Huntington’s
disease.
The direct delivery of cells to the central nervous sys-
tem is complex and presents several constraints which
must be considered when designing CRT evaluations.
First, the_current method by which cells are delivered to
the target area uses an injection-based delivery system via
a catheter/needle by which cells are deposited in beads
along a preformed track as the delivery catheter is with-
drawn (Torres et al., 2015). However, much of the cell
product is wasted, remaining within the large dead space
volume of the catheter and much of the successfully
delivered cells reflux back along the catheter track, lead-
ing to poor and uneven distribution of the transplanted
cells. The development of improved devices and methods
to combat these issues, along with their evaluation, are
key components of trials evaluating CRT.
Second, the need to proceed with very small cohorts at
this early experimental phase for safety reasons and the
challenge of reducing study bias due to the ethical con-
troversies around sham surgery are important considera-
tions in the initial study design framework. Limited
availability of sufficient foetal tissue of suitable quality
dictates that transplants must occur sequentially and with
significant time intervals. Furthermore, the effect of CRT
on functional outcomes being a combination of the effect-
iveness of the cell-delivery device, the environmental inte-
gration of transplanted cells and the lag period between
transplantation and any functional improvement being
observed must also be considered.
Here, we present the protocol for the TRIDENT study
(in recruitment at the time of writing) in which we plan
to evaluate CRT in Huntington’s disease, with a view to
developing innovative approaches that will minimize the
impact of such constraints and maximize efficiency in fu-
ture trials of CRT and similar therapies in Huntington’s
disease and other related disorders.
Methods
Study design, setting and sample
size
TRIDENT is a phase I, single centre, Trial Within a
Cohort (TWiC) (Relton et al., 2010) designed to assess
the safety and feasibility of increasing the number of
human foetal cells transplanted (compared to the previous
studies) intra-striatally into people with Huntington’s dis-
ease. It is recognized that evaluation of complex surgical
interventions, such as CRT, may require an extended ser-
ies of iterative pilot studies in preparation for randomized








s/article/3/1/fcaa230/6104885 by guest on 17 M
ay 2021
controlled trials (Craig et al., 2008; Eldridge et al.,
2016). The design of this study has been guided by the
output of the international workshop on trial design and
ethics conducted as part of the REPAIR-HD consortium
(Repair-HD Workshop Practicalities & Ethics of Trial
Design). Key components of the design include longitu-
dinal follow-up and selection of participants to receive
the intervention using a trial within a cohort design, an
in-depth deconstruction of the patient, carer and health
professional experience at each stage of the process, lead-
ing to the development of a fidelity monitoring and
health economic framework (Blencowe et al., 2015). The
TWiC design has been adopted to minimize bias intro-
duced from an inability to blind the intervention and to
use routinely collected [as part of an ongoing worldwide
observational study (www.enroll-hd.org) assessment data
as far as possible to reduce participant burden. We will
recruit a minimum of 18 and maximum of 30 partici-
pants to form the TRIDENT observational cohort, from
whom functional outcome data will be collected at speci-
fied time points (Fig. 1). A sub-set of the cohort will be
approached to undergo pre-operative assessment to deter-
mine their suitability to receive the cell-transplant surgery
(the surgical sub-cohort) and from this sub-cohort, up to
five participants will receive the cell-transplant interven-
tion. Participants selected to receive the cell transplant
will undergo additional immunological and imaging
assessments (outlined in further detail below) before and
after the surgery. This study and surgery will be per-
formed at University Hospital Wales, Cardiff, UK.
Functional assessments will be completed at the South
Wales Huntington’s disease clinic in Cardiff.
The sample size has been guided by the standard ap-
proach to phase I trials which restricts the number of
participants being asked to take part in a highly novel,
high-risk trial (McCulloch et al., 2009), whereas allowing
for a number of trial processes (such as randomization,
surgical procedure and process evaluation) to be
evaluated.
Study objectives
The primary objective of TRIDENT is to evaluate the
safety of transplantation surgery using a greater number
of human foetal striatal cells than used previously for the
treatment of people with Huntington’s disease.
Secondary objectives for the study include:
(1) definition of a framework for assessing the fidelity of
cell-transplantation procedures and surgical delivery
devices;
(2) exploration of effect estimates (through interrogation of







































Figure 1 TRIDENT trial design.








s/article/3/1/fcaa230/6104885 by guest on 17 M
ay 2021
variance of the measures across the whole cohort) to in-
form sample size calculations for future trials;
(3) evaluation of the feasibility of a health economic evalu-
ation for future trials;
(4) exploration of attitudes and understanding, feasibility
and acceptability of this process in Huntington’s disease
patients and their family members/carers, trial deliver-
ers and health professionals;
(5) capture of the social experience of patients and family
members/carers over the entire lifecycle of the cell-trans-
plantation process, including the time period before,
during and after the event;
(6) identification of the support needs of patients under-
going neural transplantation and their family members/
carers;
(7) exploration of the expectations, attitudes and clinical
equipoise of health professionals engaged in the activity
of neural transplantation towards the transplantation
process and trial processes (e.g. randomization).
Recruitment and participant
selection
Potential participants will be identified initially through
the longitudinal study CAPIT-HD2 (Core Assessment
Protocol for Intracranial Transplantation, developed in
REPAIR-HD) (www.repair-hd.eu) and latterly the global
platform study Enroll-HD (www.enroll-hd.org) via the re-
gional Huntington’s disease clinic in Cardiff. Written in-
formation will be given to potential participants either at
their routine clinic appointment or via letter prior to a
clinic visit. All potential participants will be invited to
discuss the study with the research team prior to giving
informed consent.
Participants will be eligible for entry into the observa-
tional cohort if they meet all of the inclusion criteria and
none of the exclusion criteria described below.
Inclusion criteria: (i) confirmed diagnosis of
Huntington’s disease through genetic testing (CAG repeat
length must be 39), (ii) 18 years of age, (iii) stage I or
stage II disease (defined by a total functional capacity
score, 12) and diagnosed as having motor symptom
onset, (iv) participant is ambulatory and (v) participant
must have capacity to provide informed consent.
Exclusion criteria: any ongoing major psychiatric dis-
order that would preclude the ability to take part in
functional assessments or give informed consent.
Participants in the observational cohort will be
reviewed by medically qualified members of the research
team in line with the additional exclusion criteria for
entry into the surgical sub-cohort outlined below. Those
who are potentially eligible for inclusion in the surgical
sub-cohort will be approached by the research team and
will be invited for an in-depth discussion of the cell-trans-
plant intervention with the chief investigators prior to
informed consent being taken for pre-operative
assessment.
Further exclusion criteria for entry into the surgical
sub-cohort include: (i) the lack of a carer, significant
other or family member to support attendance at regular
assessments, (ii) ongoing use of anticoagulant medication,
(iii) any significant medical condition that would com-
promise the safety of anaesthesia and/or surgery, (iv)
deemed to be unsuitable for transplant surgery (e.g. inad-
equate striatal volume), (v) pregnancy and/or breastfeed-
ing, (vi) previous immunizing event such as blood
transfusion or previous transplant, (vii) contraindications
to 3T MRI, (viii) contraindications to PET, (ix) any
contraindication to immunosuppressive therapy, (x) any
degree of chronic kidney disease, (xi) any positive blood
test for HIV, Hepatitis B, Hepatitis C, active cytomegalo-
virus, active Toxoplasma Gondii, Human T-cell lympho-
tropic virus type 1, serology for active Treponema
pallidum and (xii) females of child-bearing potential, or
males with a partner of child-bearing potential, who will
not commit to the prevention of pregnancy while enrolled
in the study.
Informed consent
Owing to the TWiC design with a sub-cohort nested
within the main observational cohort, the trial will use a
multi-stage consent model (Bibby et al., 2018). Although
there is evidence that people with HD can give valid con-
sent to participation in an innovative and complex trial
which is long-lasting (De Langavant et al., 2015), the
trial design meant that it was necessary to consent partic-
ipants only to those procedures that they would be
expected to undergo. All participants will be required to
give written informed consent prior to enrolment in the
observational cohort. Those participants asked to be
included in the surgical sub-cohort will need to provide
further written informed consent for the pre-operative
screening assessments required for sub-cohort inclusion
following further discussion of the study with the chief
investigators. This conversation will be recorded, tran-
scribed and a summary of the transcript will be sent
back to the participant as an aide memoir for their deci-
sion making. Participants will be given a minimum of
2 weeks following this discussion to decide about their
participation in the surgical sub-cohort. For the surgical
sub-cohort, informed consent can only be obtained by
the chief investigators. Finally, participants deemed suit-
able for surgery and who are selected to receive the cell
transplant will be asked to provide written informed con-
sent for the surgical procedure and assessments linked to
having the surgery. This will be obtained by either of the
chief investigators, but additional clinical consent will be
obtained by the neurosurgical chief investigator perform-
ing the cell transplant prior to hospital admission in line
with local clinical practice. At each stage, as part of the
informed consent process, potential participants will be
counselled about the inability to take part in other clinic-
al trials where they have the possibility of receiving other
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novel potential disease-modifying therapies while partici-
pating in the TRIDENT trial. For participants who re-
ceive the CRT, this is likely to be a long-term
consequence of participation in TRIDENT and this will
be expressly noted prior to obtaining consent for surgery.
For participants who remain in the observational cohort
only, they will be free to take part in other clinical trials
once their 12-month assessment has been completed.
Where family members or carers and trial delivery staff
are requested to take part in qualitative interviews, indi-
vidual written informed consent will be sought prior to
interviews taking place.
Study outcomes
The primary outcome measure for this trial will be safety
at 4 weeks after surgery as defined by (i) the lack of inci-
dence of significant additional, permanent neurological
deficit, (ii) the lack of incidence of a clinically significant
intra-cranial haemorrhage and (iii) the lack of incidence
of clinically significant intra-cranial infection. All aspects
of the primary outcome will be assessed and decided by
the independent trial steering committee (TSC).
The secondary outcomes of this study will be; (i) feasi-
bility and acceptability of clinical trial processes as deter-
mined by recruitment, retention and participant and carer
experiences, (ii) fidelity of neurosurgery defined by the
evaluation of successful delivery of cells and accurate
neurological graft placement, (iii) long-term (12 months)
safety of transplantation defined by growth profile of
graft and the absence of development of clinically signifi-
cant inflammatory and/or immune reaction, (iv) documen-
tation of research, treatment and immunosuppression
costs as well as feasibility of collection of patient-reported
outcome measures to aid the development of a full-health
economic evaluation in future trials and (v) development
of fidelity markers through analysis of the surgical pro-
cedure and graft survival over 12 months.
Observational cohort assessments
Participants in the observational cohort will undergo
assessments at baseline, six (62 weeks) and 12 months
(64 weeks) (Figure 1). At baseline and 12 months, this
includes the SF-12 questionnaire of health-related quality
of life (Ware et al., 1996), the Client Service Receipt
Inventory (CSRI) (Beecham and Knapp, 1992) and the
CAPIT-HD2 (Supplementary Table 1) functional assess-
ment battery (Table 1). CAPIT-HD2 was developed as
part of the REPAIR-HD study (www.repair-hd.eu) and
tests across motor, cognitive, psychiatric and functional
domains using a number of widely used and validated
measures as well as novel evaluations. At the 6-month
time point, participants are assessed on only a truncated
CAPIT-HD2 battery as summarized in Table 1. Owing to
the nature of the intervention, assessments will not be
blinded. However, to mitigate these limitations as far as
possible, the Unified Huntington’s Disease Rating Scale
(Huntington Study Group, 1996) will be recorded as
video for rating by an independent assessor, and partici-
pants will wear a head covering to blind the assessor to
their surgical status.
If the participant has performed an Enroll-HD assess-
ment in the preceding 8 weeks to their TRIDENT assess-
ment, data from common measures will be taken from
Enroll-HD to prevent repeated exposure effects on cogni-
tive assessments and minimize participant’s burden.
Observational cohort participants will be offered the
opportunity to co-enrol in the HD-Clarity study (www.
hdclarity.net), a global biobanking project collecting cere-
brospinal fluid (CSF) from people with Huntington’s dis-
ease for biomarker analysis. Lumbar punctures to collect
CSF would be performed at the baseline or 6-month
assessments. For participants who then go on to have the
CRT intervention, this CSF sample would be used for im-
munological marker analysis as the pre-operative
baseline.
Pre-operative screening assessments
Participants who are believed to be suitable to receive the
cell-transplant therapy will be asked to consent to pre-op-
erative screening to formally assess their suitability
against the study inclusion/exclusion criteria. These
assessments will be staged to minimize participant’s bur-
den and risk. Blood tests to screen the health of partici-
pants will be performed. These will include standard pre-
operative biochemistry and coagulation as well as a full
virology and serology panel to determine the presence of
infective agents (see exclusion criteria for detail). A blood
sample will be retained for analysis of immunological
markers in those participants who go on to have the
CRT intervention. Serum pregnancy testing will be con-
ducted in female participants. A 12-lead ECG will also
be performed.
If the participant remains suitable for surgery after the
blood tests and ECG, then they will undergo a 1.5T or
3T (if available) MRI under general anaesthetic. The scan
serves two purposes: ensuring sufficient striatal volume
for transplant and use for surgical planning. If the scan
reveals insufficient striatal volume for transplant, then
that participant will remain in the observational cohort.
Participant selection for CRT
If participants have been deemed eligible for surgery
through the pre-operative screening process, they will be
considered to be in the surgical sub-cohort. From this
sub-cohort, the clinical and surgical team will make a de-
cision on the best first candidate in terms of clinical pro-
file, social support and surgical safety to undergo the
first CRT operation. Subsequent participants for CRT
will be selected at random from the surgical sub-cohort
to provide a direct assessment of willingness to be
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Rating Scale (Total Motor
Score)b,c
The Unified Huntington’s Disease Rating Scale is the gold standard measure for assessing motor severity in peo-




Participants are required to tap their index finger on a force transducer according to cues. The duration and
variability of finger taps are recorded (Reilmann and Schubert, 2017)
Dynamic cue and force
matching
Participants are required to grip and lift a device fitted with a force transducer and hold it stable. Grip force, 3D
position and orientation of the object are recorded (Medzech et al., 2019)
Grasping and lifting Participants are required to complete a series of tests where they generate force on a transducer with their
index finger. They will be asked to; match force patterns for which they have previously received visual feed-
back, match a sinusoidal pattern, generate increasing and decreasing force patterns with and without visual
feedback. Deviations from target forces and patterns are recorded
Q-Traild Participants are required to make a trail between specific numbers and/or letters using a stylus on a force trans-
ducer. Total distance travelled, total time used, precision of target identification (including total errors) and
path precision are recorded
Q-Eyec,d Participants are required to look at visual stimuli on a projected screen while their head is stabilized using a
brow bar and chin rest. Eye movements (saccades, smooth pursuit and optokinetic nystagmus) in response to
the stimuli are recorded
Cognitive domain
Mattis Dementia Rating Scalec The Mattis is a well-documented global measure of cognitive status, especially sensitive in sub-cortical affections
(Mattis, 1976)
Hopkins Verbal Learning Testc The HVLT is composed of 12 items, organized into three semantic categories and presented over three con-
secutive learning trials (Brandt, 1991)
Controlled Oral Word
Association Tests (COWAT)
Participants are asked to name as many words (excluding proper nouns) beginning with a specific given letter
(Loonstra et al., 2001; Ardila et al., 2006)
Category Fluency Participants are asked to name as many things in one category as possible in a given time (usually 60 s) (Lezak,
1995)
Stroop testb,c Participants are presented with a series of words pertaining to colours and are asked to read them out loud.
Initially, the words are coloured to correspond to the word. Participants are asked to repeat the task with
words written in contrasting colours, but they have to say the name of the colour the word is written in
(Stroop, 1935)
Symbol Digit Modalitiesb,c Participants are presented with a series of symbols and a code assigning a number (1–9) to each symbol. They
have 90 s to write the corresponding number for the symbol for as many symbols as possible (Smith 2007)
Relationship and Life Eventsd The relationship questionnaire is composed of 48 items. For each question, six possible responses are proposed:
‘absolutely true’, ‘true’, ‘mostly true’, ‘mostly false’, ‘false’ and ‘absolutely false’. The assessment of life events
will be performed by using the Holmes & Rahe Scale (Holmes and Rahe, 1967). Patients are asked to tally 43




This is a semi-structured clinical interview measuring the presence, severity and frequency of 11 key behavioural
symptoms. Detailed severity scoring criteria are provided for each item (Craufurd et al., 2001)
Apathy and Irritability Scalesc These are standardized questionnaires to assess apathy and irritability (Snaith et al., 1978; Marin et al., 1991)
Modified Frontal Systems
Behavioural Scale
This is a brief, participant completed behaviour rating scale with demonstrated validity for the assessment of be-
haviour disturbances associated with damage to the frontal–subcortical brain circuits (Duff et al., 2010)
Maze Taskc,d Participants are asked to make decisions when offered a choice between objects (decision making under limited
choice) and when there is no list of options to select from (decision making under unlimited choice).
Participants are told to make the decision as quickly as they can. The decision outcome is then recorded
Persistence Taskc,d This is intended to assess loss of motivation (an aspect of apathy). Participants are informed that they must race
their icon against an opponent’s icon. They are also informed that their icon is fitted with a speed boost that
the computer will activate at a random point in the race. Latency to quitting/completion is measured
(McLauchlan et al., 2019)
Functional domain
Unified Huntington’s Disease
Rating Scale Total Functional
Capacityc
The Unified Huntington’s Disease Rating Scale TFC scale assesses how people with HD manage their work,
finances, daily living, domestic chores and care arrangements (Huntington Study Group, 1996)
C3Tc,d The Clinch Token Transfer Test (C3T) is a dual-task assessment of bilateral, upper motor function that consists
of three coin-transfer tasks which increase in difficulty (baseline simple, baseline complex and a dual task).
The time taken to pick up and transfer the coins from the dominant to non-dominant hand and place into a
purpose developed box is recorded. The addition of cognitive load increases the task complexity (Clinch
et al., 2018)
aAll assessments are conducted at baseline and 12 months.
bAssessments included in the 6-month truncated assessment battery.
cAssessments required for the minimum data set.
dNovel assessment.








s/article/3/1/fcaa230/6104885 by guest on 17 M
ay 2021
randomized to a CRT intervention. This will be done
using a set of computer-generated random numbers to
order the participants in the surgical sub-cohort. Where
participants assessed for surgery either decline inclusion
in the surgical sub-cohort or are found not to be suitable
to proceed with the surgical intervention, they will re-
main as participants in the observational cohort.
Cell-replacement therapy (study
intervention)
Selected participants will be required to repeat baseline
assessments if these were initially completed more than
6 weeks prior to surgery. A 3T MRI will be performed in
the month prior to surgery for microstructure analysis
and again at 1 month post-operatively. If the participant
exhibits marked chorea, they may be given an anti-
choreic medication prior to the scan to minimize move-
ment artefacts. PET scanning using 18F-Fallypride will
also be performed in the month prior to surgery to visu-
alize striatal function. Urine pregnancy tests will be per-
formed in female participants prior to PET scanning.
Furthermore, a contrast CT angiogram will be performed
in the month prior to surgery to visualize blood vessels
for surgical planning.
Foetal cell preparation
Foetal cells for transplant are processed for use by the
Cardiff Fetal Tissue Bank. This is a Human Tissue
Authority accredited (Human Tissue Authority license no.
22639), REC approved (Ref 18/WA/0204), Good
Manufacturing Practice facility licensed for the harvest
and preparation of donated foetal tissue for cell trans-
plant. Following informed consent potential maternal tis-
sue donors are screened for presence of infectious agents
prior to collection of tissue. foetal tissue and associated
products are also tested for the presence of pathogens
throughout the preparation process. foetal samples be-
tween 8 and 14 weeks gestation are collected and are
staged developmentally using both intrauterine ultrasound
measurements (pre-collection) and direct morphometric
measuresments foetal parts (post-collection). Thus, al-
though some variation in development age is inherent to
this process, accurate data will be available for correl-
ation with study outcomes. Due to the short time lines
between collection and implantation, no characterization
of the tissue is possible other than defining the gestation-
al stage and ensuring sterility. Once collected, foetal tis-
sue is transferred to the Cardiff Fetal Tissue Bank and
whole ganglionic eminences are dissected for storage
(maximum 7 days) in hibernation medium until the day
of surgery. The process for preparing foetal tissue for
transplant and the required sterility monitoring is detailed
in Roberton et al. (2018). The resulting cell suspension is
made to the required cell density and examined for via-
bility (which must be 80% for transplant) before imme-
diate transfer to the operating theatre for use within 8 h.
Cell-delivery device
To deliver the foetal cells to the striatum, a CE-marked
device manufactured by Elekta (Stockholm, Sweden) with
an in-house-manufactured inner cannula will be used.
The Elekta outer cannula is a sterile stainless steel
Backlund Injection device designed for use with the
Leskell stereotactic frame and can be coupled with Luer-
locked syringes for intra-cranial injection of substances.
To our knowledge, the Elekta cannula has not, itself,
been used for direct intracranial injection of cells previ-
ously although it was used as a guide cannula in the
ReneuronV
R
Pisces trials (Kalladka et al., 2016). The inner
cannula fits inside the Elekta device and can be coupled
to the injection system. The inner cannula is single-pa-
tient use and will be pre-loaded with cell suspension prior
to insertion into the outer Elekta cannula, and hence
multiple inner cannulas can be used in each surgery de-
pending on the number of donor cells available and injec-
tion tracts made.
Surgical procedure
The cell-transplant surgery will be conducted under gen-
eral anaesthetic by an experienced consultant neurosur-
geon (Co-Chief Investigator) highly familiar with
sterotactic surgery and the apparatus used. Cannula tra-






(www.renishaw.com) robot guidance for
manual advancement of the cannula to the target area.
The inner cannula, pre-loaded with foetal cells will then
be used to deliver them. Up to six tracts will be made
per striatum (two in the caudate, two in the anterior pu-
tamen and two in the posterior putamen), based on stri-
atal volume. Each tract will consist of up to five deposits
of cells at 1–2 mm intervals as the needle is withdrawn.
In the first surgery, a total of 12 million cells will be
injected in a uni-lateral transplant.
The first participant will receive a unilateral transplant
and, if this is deemed safe after a TSC review, we antici-
pate inviting this participant to undergo a similar trans-
plant (same number of cells) in the other hemisphere
with at least 6 weeks inbetween surgeries. The ideal time
window between surgeries is not known. In their success-
ful pilot study of five individuals, Bachoud-Lévi et al.
performed staged surgical implantations a year apart. In
the MIG-HD study, the gap between surgeries was only
4 weeks and few participants had good functional
grafts, as judged by raclopride and fluorodeoxyglucose
PET (Bachoud-Lévi et al., 2020a), raising the possibility
that this short gap increased the risk of alloimmunization
(Bachoud-Lévi et al., 2020b). However, the relationship
between the existence of graft-associated antibodies and
poor graft survival in MIG-HD was not clear and there
were several other potential reasons for the poor graft
survival (Bachoud-Lévi et al. 2020b). Given the theoretic-
al possibility that alloimmunization is associated with an
inter-surgical gap of just a few weeks, the precise gap is
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currently under review and may be guided by the pres-
ence of antibodies (in blood and CSF).
For subsequent participants, the CRT intervention may
be delivered as a single-stage bi-lateral procedure, but
will be based on clinical judgement of the surgical and
clinical team with expert input from the TSC. It is antici-
pated that the second participant will receive an increase
of 2.5 million cells per striatum and that this will con-
tinue with each subsequent surgery to a maximum of 22
million cells per striatum.
Immunosuppression
Participants will undergo a period of immunosuppression
that is expected to last at least 12 months (from the last
surgery in the case of sequential uni-lateral transplants)
to prevent graft rejection. The regime selected is a stand-
ard protocol for preventing donor tissue rejection after
organ transplant and consists of: tacrolimus, 0.1 mg/kg
for 12 months; mycophenolate mofetil, 500 mg twice daily
for 12 months; prednisolone, 20 mg/day with staged re-
duction to be steroid free by 8-week post-surgery, cefo-
taxime on the day of surgery, co-trixamole, 480 mg/day
for 6 months and nystatin for 14 days. Levels of tacroli-
mus will be monitored closely at the start of immunosup-
pression and throughout to achieve a consistent blood
trough level of 4–7 lg/l. Dose modification of mycophe-
nolate mofetil may be necessary if a participant develops
neutropenia. Participants will be provided with a medica-
tion diary as a reminder to take the correct immunosup-
pression and compliance will be monitored at each
follow-up visit (Supplementary Table 1). Restricted medi-
cations include any of those listed in the Interaction with
other medicinal products section (section 4.5) of the sum-
mary of product characteristics of any of the immunosup-
pressive drugs listed above. Participants are permitted to
continue with any medications prescribed for their disease
as long as they are not in the list of restricted drugs.
Female participants will undergo monthly urine preg-
nancy tests and, should pregnancy occur, we will follow
local procedure for managing pregnancy in those on im-
munosuppression for solid organ transplant, where taroli-
mus is continued but dosage may need to be adjusted
and mycophenolate is switched to azathioprine.
Post-operative follow-up and
assessments
Participants who have received the CRT intervention will
be followed closely according to the schedule indicated in
Supplementary Table 1. In addition to tacrolimus moni-
toring, blood will be analysed (biochemistry panel) to
monitor health. Analysis of immunological markers
[human leucocyte antigen and non-human leucocyte anti-
gen antibodies, peripheral blood monocytes (phenotypic
and functional analysis of T and B lymphocytes plus nat-
ural killer cells)] will be performed on blood and CSF
samples taken at specified time points as indicated in the
schedule of assessments (Supplementary Table 1). In the
event that a participant needs to cease immunosuppres-
sion, additional CSF samples will be collected 1 month
prior to and post-cessation of the immunosuppression.
Urine pregnancy tests will be performed at least monthly
in female participants on immunosuppression. One month
after surgery transplant recipients will require a further
1.5T MRI scan to check graft placement. The 3T MRI
scan and PET scan will be repeated at 12 months for
microstructure comparison with the pre-operative scan
and to assess functional integration of the graft, respect-
ively. For all post-operative scans, if participants exhibit
chorea likely to affect the image quality, then they will
be given anti-choreic medication prior to the scan.
Functional assessments will be performed at 6 and
12 months in line with those undertaken in the observa-
tional cohort. Adverse event and safety monitoring will
be performed at each follow-up visit and all adverse
events will be recorded. Any unexpected serious adverse
events will be reported locally and to the appropriate eth-
ics committee. Participant follow-up will continue after
the end of the trial via the South Wales Huntington’s dis-
ease clinic.
Monitoring
The primary objective of the trial, safety, will be
reviewed and assessed by the TSC on a per-transplant
basis. The TSC will consist of independent experts, cover-
ing the areas of neurosurgery, immunology, CRT and
Huntington’s disease. The TSC will convene 4–6 weeks,
following each surgery to review anonymized data
(including pre- and post-operative MRI scans, operative
and in-patient notes containing all blood results) from
participants who have received CRT intervention to de-
termine if the primary safety outcome has been met and
if the trial should be halted for any reason. The TSC will
be asked to pay specific attention to the following poten-
tial issues; the presence of a significant amount of mater-
ial outside the target area of the striatum as visible on
MRI, any abnormality on the post-operative scan that is
linked to a functional deficit, any unexpected complica-
tion of surgery, to include any breaks, bends or block-
ages of the cell-delivery catheter or any other intra-
operative or procedural concerns.
In addition to safety reviews on transplanted partici-
pants, the TSC will also be asked to review advances in
the neural cell-transplantation field, with specific reference
to cell-delivery systems. If it is felt that during the trial, a
superior device for delivering cells to the target area of
the striatum has become available, the interventional part
of the trial will be paused. To make this happen, we
would seek to re-start the trial using the superior device.
Due to the small numbers involved, no additional data-
monitoring committee will be convened.
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Participant’s withdrawal
Participants will have the right to withdraw fully or par-
tially from the trial at any time. However, it will be
made clear to participants going forward for surgery,
once they have received the cell transplant, which they
will need to remain in follow-up for safety reasons.
However, participants would be permitted to withdrawal
from further functional assessments.
Process evaluation
All participants selected to undergo transplant surgery will be
invited to take part in a series of brief semi-structured, in-depth
interviews prior to and following their operation. Family mem-
bers and/or carers of the participants may also be interviewed.
The interviews will explore participants’ understanding of neur-
al transplantation, perceptions and concerns and actual experi-
ences of the cell-transplantation process. These interviews will
also provide insight to key elements of trial design (feasibility
and acceptability). A number of participants (anticipated sam-
ple size, 3–5) from the trial observational cohort will also be
interviewed to gain their views and understanding on random-
ization, the consent process and participant materials, which
can be contrasted with the views of those in the transplanted
cohort.
Interviews will also be conducted with the health pro-
fessionals involved in the recruitment and consent of par-
ticipants, the surgical staff involved in the transplant
process and with research staff involved in the comple-
tion of follow-ups and data collection. This will provide
insight into trial design and feasibility, clinical equipoise
and patient selection as well as views on CRT.
Health economics
No formal health economic evaluation will be undertaken
as part of this study but feasibility of collating health
economic data in this participant population and for the
CRT intervention will be assessed to inform future health
economic evaluations in later efficacy trials. This will in-
clude the exploration of the feasibility, acceptability and
sensitivity of collecting standard patient-reported outcome
measures such as SF-12 compared to condition-specific
questionnaires, collecting costing information during sur-
gery to allow micro-costing of the intervention and using
the CSRI to collect healthcare resource use information
to estimate changes in healthcare cost in addition to im-
plementation costs from both NHS and partial societal
perspectives. Details of the health economic evaluation




All data will be collected and stored using a unique par-
ticipant identification number to ensure confidentiality.
All assessment data will be entered into the trial database
with in-built range checks and data validation to ensure
the accuracy of data collected. Where assessment data are
to be obtained from Enroll-HD, this will be via an
Enroll-HD-specific data request. Specific data manage-
ment procedures are detailed in the trial data manage-
ment plan.
Statistical analysis
This study will involve descriptive analysis of clinical out-
comes (Table 1) only. Continuous variables will be sum-
marized as means and standard deviations, or medians
and interquartile ranges if more appropriate, by sub-co-
hort (i.e. whether they did or did not receive CRT) and
separately per time point (baseline, 6 and 12 months).
Similarly, categorical variables will be summarized as fre-
quencies and percentages, by sub-cohort and per time
point. The group of participants who did not receive
CRT will potentially be further divided into those who
were initially selected and approached but did not receive
the neural transplantation (e.g. refusal or ineligibility for
surgery) and those who were never selected. In brief,
95% confidence intervals may be calculated for differen-
ces of group means or medians, but no formal statistical
hypothesis testing will be performed.
Exploratory evaluations will be carried out to explore
plausible trial designs for subsequent randomized trials
evaluating the efficacy of neural transplantation in this
population. Design considerations and parameters of
interest will be detailed separately in the statistics and
health economics analysis plan.
Qualitative analysis
Transcribed interviews will be subject to framework ana-
lysis incorporating thematic and case analysis (Gale et al.,
2013) to allow for different data sources and diverse
sampling. Minutes from trial management group meetings
will also be included to identify themes pertinent to trial
development and delivery. Agreement on concepts and
coding between members of the research team will be
sought and 20% of data will be coded by different team
members to check coding scheme reliability. The complete
description is given in the qualitative analysis plan.
Ethics approval and consent to
participate
Ethical approval for the study was given by Wales
Research Ethics Committee 3 on 08/06/2018, Reference:
18/WA/0182. All participants must give full written,
informed consent prior to inclusion in the study. This
includes consent to participate for all qualitative inter-
views. All protocol amendments will be reported via
ISRCTN.
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Data availability
Requests for access to trial data can be made to CTR@
cardiff.ac.uk. The sharing of trial data will be pursuant
to review of consent and contractual requirements.
Discussion
The TRIDENT trial aims to assess the safety and feasibil-
ity of CRT [including the safety of transplanting a larger
numbers of cells than used in our previous UK study
(Rosser et al., 2002)] for people with Huntington’s dis-
ease, while exploring a number of methodological issues
to inform future trial designs. Key methodological, surgi-
cal and ethical challenges surrounding the investigation of
CRT were identified through previous activities of the
REPAIR-HD consortium (www.repair-hd.eu) and latterly
through activities of the international networks Stem
Cells for Huntington’s Disease and European
Huntington’s Disease Network Advanced Therapies
Working Group and Surgical Delivery Task Force (www.
ehdn.org/advanced-therapies-wg). These challenges in-
clude: delivery device performance and surgical fidelity;
methodology governing precise cell delivery; minimization
of study bias; requirement for long-term follow-up (given
the lag time between transplantation and measurable
functional benefit being observed); limited availability of
foetal tissue and the need to proceed cautiously with
small clinical study cohorts for reasons of safety.
Here, we present a protocol for investigating CRT in
Huntington’s disease whose design is centred around
addressing some of the aforementioned constraints and
challenges involved in CRT research. The TWiC design
(Relton et al., 2010), in which participants are randomly
selected (following eligibility screening) to receive the sur-
gical intervention from a pool of participants in whom
longitudinal clinical data are collected, has been adopted
for the benefits it offers in terms of efficiency (Van Der
Velden et al., 2017), pragmatism and potential reduction
in disappointment bias (Relton et al., 2010).
Given the ethical concerns inherent in sham surgery,
achieving double blinding in CRT research is challenging.
Although this is not a particular concern in this trial, as
we are primarily concerned with surgical safety, we have
taken steps to minimize bias as far as possible through
masking of rater-administered assessments. Bias is being
addressed further through ongoing work focussing on the
development of quantitative clinical outcome measures
using digitized objective assessments. There are, of course,
limitations to this. For example, this study (and previous
similar studies to date) does not control for the use of
immunosuppressives that could theoretically have a neu-
roprotective effect (Matsumoto et al., 2018; Jung and
Yoon, 2020). Ultimately, these issues may impose the
need for sham controls in the future, although it is also
worth highlighting that instances of graft failure (i.e. a
graft that does not survive) can be used to provide a
comparison equivalent to sham surgery. Specifically,
transplanted cells that fail to survive or integrate can pro-
vide no functional benefit and hence the participant
would have been exposed to all the procedures associated
with CRT without the benefit of a healthy surviving
graft, in contrast to sham surgery which generally only
reproduces some elements of the surgical process and
stops short of brain penetration. For future trials where
investigation of efficacy is the primary focus, it may be
appropriate to perform sham surgeries and this would be
judged on its merits at the time, and would require modi-
fication to the trial design.
Evaluation of CRT is likely to require a number of
small, iterative pilot studies to assess safety and feasibility
and explore effect estimates and study design aspects
prior to moving forward with randomized controlled tri-
als for assessing efficacy. Here, the use of the TWiC de-
sign promotes efficiency through the development of a
cohort with periodic and longitudinal collection of func-
tional outcome data with the possibility of cohort expan-
sion across time. This, therefore, allows the possibility for
testing more than one intervention, over time, within the
cohort (Relton et al., 2010). This is particularly advanta-
geous in a rare disease such as Huntington’s disease
where the number of potentially eligible participants for
such interventions is limited. However, the degenerative
nature of Huntington’s disease would require careful par-
ticipant selection to ensure that those in the intervention
cohort are sufficiently similar to those in the cohort act-
ing as controls. Furthermore, the potential for longitudin-
al data collection (a defining feature of cohort studies) is
attractive for studies investigating the safety and utility of
novel procedures, and those using novel devices, as it
allows for the ongoing collection of safety data which is
a vital part of the regulatory pathway.
CRT may prove to be a beneficial therapeutic strategy
in neurodegenerative disorders other than Huntington’s
and Parkinson’s disease, particularly in those in which
there is a relatively focal anatomical distribution of neur-
onal loss. As an autosomal dominant disorder with al-
most complete penetrance, Huntington’s disease can be
diagnosed with confidence in life, making it a powerful
paradigm for understanding and treating other neurode-
generative conditions. Thus, it is anticipated that identify-
ing the principal requirements for successful CRT
through this and future trials will eventually be applicable
to similar research in other disorders of the central ner-
vous system.
The complexities of addressing the challenges and con-
straints facing CRT research and how this can be trans-
lated into clinical practice in the future have highlighted
the requirement for thorough and transparent reporting
of studies of advanced therapies (to include CRT and
other novel therapeutic strategies such as anti-sense oligo-
nucleotides and gene therapies). The template for inter-
vention description and replication (Hoffmann et al.,








s/article/3/1/fcaa230/6104885 by guest on 17 M
ay 2021
2014) provides a framework for ensuring the comprehen-
sive description of complex interventions such as CRT in
the first instance to ensure transparency and allow repli-
cation. However, CRT comprises several critical interven-
tional components, not least an intricate surgical
procedure requiring significant experience and expertise,
all of which need careful consideration as the field of
advanced therapies research in Huntington’s disease and
other neurodegenerative disorders develops and moves to-
wards realistic therapies. To ensure consistency and com-
parison across studies with multiple therapeutic moieties,
research teams and study designs, a framework for re-
search progression should be followed. We suggest that
an appropriate solution would be to develop an expan-
sion to the Idea, Development, Exploration, Assessment,
Long-term follow-up (IDEAL) framework (McCulloch
et al., 2009), originally developed to describe the stages
of innovation in surgical process with recommendations
on how to approach each stage. Since the inception of
the IDEAL framework, it has been expanded to include
guidance for innovation in physiotherapy (Beard et al.,
2018) and medical devices (Sedrakyan et al., 2016) and
could be adapted again to incorporate advanced therapies
for neurodegenerative disorders. Having such a frame-
work for development would enable consistency in the
development of advanced therapies, thus enabling more
straightforward comparison of novel interventions for the
treatment of neurodegenerative disease.
A unique aspect of the TRIDENT trial is that, unlike
many early-phase trials, it includes a comprehensive pro-
cess evaluation as a core outcome. This is being under-
taken at this early stage with the intention of
documenting the intricacies of conducting CRT research
from both the perspectives of participants involved and
from those tasked with its delivery. We believe that
understanding these processes as fully as possible is vital
for developing robust methodology for future studies.
The inclusion of a process evaluation at this juncture
also serves to highlight a fundamental aspect underpin-
ning the design of TRIDENT, which has been to embed
public and patient involvement (PPI) throughout. Many
of the ethical and logistical challenges of pursuing re-
search of this nature were voiced at the REPAIR-HD
workshop on the practicalities and ethics of trial design
(‘Repair-HD Workshop Practicalities & Ethics of Trial
Design’) where invited PPI representatives were involved
in the co-production of the workshop outputs. At this
workshop, it was noted that participants and their fami-
lies should be considered partners in the research and
that researchers should be mindful that the study out-
comes relate to what people with Huntington’s disease
actually want. At all stages, we have engaged with our
PPI partner with reference to study design and all logis-
tical aspects of trial delivery, which has been facilitated
by the presence of our PPI partner at regular trial man-
agement group meetings. In our experience, the inclusion
of our PPI partner has proved an invaluable resource in
keeping the participant voice at the forefront of what we
are trying to achieve.
TRIDENT will test the safety of a potentially effica-
cious dose of primary foetal cells, giving us greater in-
sight into the potential requirements for successful CRT.
In the long term, it is unlikely that foetal cells will con-
tinue to be the primary source of tissue for CRT due to
their limited availability, the ethical issues surrounding
their use and the difficulties in standardizing processing
according to Good Manufacturing Practice. Indeed, al-
though the developmental stage of donor foetal tissue is
limited to a specific gestational window (8–12 weeks, but
in practice most tissue collections fall within an 8- to 10-
week window), each participant will be effectively trans-
planted with a different cell product which may lead to
variability in outcomes.
Replacing the donor cell source with striatal progenitor
cells derived from human pluripotent stem cells is a
plausible solution (Rosser and Svendsen, 2014). The gen-
eration of human pluripotent stem cells for use in CRT is
an area of ongoing investigation in both Huntington’s
disease (Li and Rosser, 2017) and Parkinson’s disease
(Petit et al., 2014) and their use has already been trialled,
albeit in a small, uncontrolled safety trial, as a treatment
for ischaemic stroke (Kalladka et al., 2016) and the first
stem-cell transplants trials for Parkinson’s disease have
commenced. Importantly, the information and outcomes
gathered in TRIDENT will be pivotal for establishing the
principles and generating a robust methodological frame-
work to undertake clinical assessment of the safety and
efficacy of future stem-cell sources that have been selected
through rigorous in vitro and in vivo laboratory testing.
Trial status
This trial is currently open with recruitment to the obser-
vational cohort commencing on 10 August 2018 with
plans to close recruitment to the observational cohort by
March 2021. The trial is on version 5.0 (dated 8 May
2020) of the protocol. Results of the trial will be dissemi-
nated via peer-reviewed publication and ISRCTN.
Additional communication of results will be made to trial
participants.
Supplemental material
Supplementary material is available at Brain
Communications online.
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Bachoud-Lévi A-C, Massart R, Rosser AE. Cell therapy in
Huntington’s disease: taking stock of past studies to move the field
forward. Stem Cells 2020b; 1–12. doi: 10.1002/stem.3300.
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Mazzocchi-Jones D, Döbrössy MD, Dunnett SB. Embryonic striatal
grafts restore bi-directional synaptic plasticity in a rodent model of
Huntington’s disease. Eur J Neurosci 2009; 30: 2134–42.
McLauchlan DJ, Lancaster T, Craufurd D, Linden DEJ, Rosser AE.
Insensitivity to loss predicts apathy in Huntington’s disease. Mov
Disord 2019; 34: 1381–91.
McCulloch P, Altman DG, Campbell WB, Flum DR, Glasziou P,
Marshall JC, et al. No surgical innovation without evaluation: the
IDEAL recommendations. Lancet 2009; 374: 1105–12.
Medzech S, Sass C, Bohlen S, Lange HW, Koch R, Schubert R, et al.
Impaired isometric force matching in upper and lower limbs
revealed by quantitative motor assessments in Huntington’s disease.
J Huntingtons Dis 2019; 8: 483–92.
NeuromateV
R
robotic system for stereotactic neurosurgery [Internet].
Available from: https://www.renishaw.com/en/neuromate-robotic-sys
tem-for-stereotactic-neurosurgery–10712 (18 April 2020, date last
accessed).
Petit GH, Olsson TT, Brundin P. Review: The future of cell therapies
and brain repair: Parkinson’s disease leads the way. Neuropathol
Appl Neurobiol 2014; 40: 60–70.
Reilmann R, Schubert R. Motor outcome measures in Huntington dis-
ease clinical trials. Elsevier: Handbook of clinical neurology 2017; p.
209–25.
Relton C, Torgerson D, O’Cathain A, Nicholl J. Rethinking pragmatic
randomised controlled trials: introducing the “cohort multiple rand-
omised controlled trial” design. Br Med J 2010; 340: c1066.
Repair-HD [Internet]. Available from: http://www.repair-hd.eu/ (5
April 2020, date last accessed).
Repair-HD Workshop Practicalities & Ethics of Trial Design by
Scarlet Design International Ltd.—Issue [Internet]. Available from:
https://issuu.com/scarletdesigngroup/docs/repair_hd_mapsv2_print
(17 May 2020, date last accessed).
Roberton VH, Rosser AE, McGorrian AM, Precious SV. Dissection
and preparation of human primary fetal ganglionic eminence tissue
for research and clinical applications. In: Methods in molecular biol-
ogy. Humana Press Inc.; 2018. p. 573–83.
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